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Purpose: There is a relative paucity of research regarding medication expenditure associ-
ated with multiple-therapy use for rhinitis in Australia. To describe 1) the nature and extent of 
multiple-therapy use for rhinitis in Australia using data on therapies purchased with prescription 
or over-the-counter (OTC) and 2) additional costs incurred by multiple-therapy use compared 
with intranasal corticosteroid (INCS) therapy alone.
Patients and methods: A retrospective observational study was carried out using a database 
containing anonymous pharmacy transaction data available from 20% of pharmacies in Australia 
that links doctor prescriptions and OTC purchase information. Pharmacy purchases of at least 
one prescription or OTC rhinitis treatment, with or without additional asthma/chronic obstructive 
pulmonary disease (COPD) therapy, by patients during 2013 and 2014 were assessed.
Results: In total, 4,247,193 prescription and OTC rhinitis treatments were purchased from 909 
pharmacies over 24 months. The majority of rhinitis therapy transactions were single-therapy 
purchases without additional asthma/COPD therapy. Of the single therapies purchased, 73% were 
oral antihistamines (OAHs) and 15% were INCS therapy. Dual-therapy purchases of INCSs and 
OAHs accounted for 40% of multiple-therapy purchases. Patients frequently purchased OAHs, 
nonsteroidal nasal sprays, and eye drops for allergic conjunctivitis alongside INCSs, resulting in 
higher financial costs (up to AU$21 per treatment episode) compared with INCS monotherapy.
Conclusion: This study highlighted the significant burden posed on community pharmacy to 
address the needs of people with rhinitis symptoms, and the failure to translate the evidence 
that INCSs are the most effective monotherapy for moderate to severe and/or persistent rhini-
tis into clinical practice in light of the lack of evidence supporting combination of INCS and 
OAH therapy. Health care professional engagement, especially at the pharmacy level, will be 
extremely important if we wish to ensure that the purchase of rhinitis treatment is in accordance 
with guidelines and that their use is optimal.
Keywords: community pharmacy, intranasal corticosteroids, oral antihistamines, over-the-
counter, prescription, rhinitis, therapy
Introduction
Rhinitis is not a single disease with one underlying mechanism but rather a collection 
of multiple distinct syndromes that cause similar nasal symptoms.1 Rhinitis is classi-
fied into two major subtypes – allergic rhinitis (AR), and a heterogeneous subgroup of 
conditions with various triggers and distinct pathophysiologies known as nonallergic 
rhinitis (NAR). Recent data suggest that as many as 87% of patients with rhinitis may 
have mixed rhinitis (MR), a combination of NAR and AR components.2 Untreated 
or suboptimally managed rhinitis can have a significant negative impact on patients’ 
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quality of life – impairments in work productivity, school 
performance, social interactions, and sleep.3–5 The high finan-
cial costs associated with inappropriately managed rhinitis, 
including the direct medication-related costs and indirect 
costs through lost wages and decreased productivity, pose 
a substantial economic burden on individuals and society.6,7
AR is the most prevalent form of rhinitis, affecting 
10%–40% of the global population, and its prevalence is 
increasing both in children and in adults.3 In Australia, AR 
affects 17% of the population and is predicted to increase 
in prevalence by 70% in the next 35 years.8,9 Predominant 
symptoms of AR are sneezing, watery rhinorrhea, nasal 
itching, and nasal congestion. Other associated symptoms 
include postnasal drip, throat clearing, headache and/or facial 
pain, impaired smell, itchy throat and palate, and conjuncti-
val symptoms.3,5,10–12 AR is one of the most underestimated 
respiratory conditions, by both physicians and patients. 
Its management is often suboptimal as a result of delayed 
diagnosis, uninformed attempts by patients to self-manage 
with a wide range of over-the-counter (OTC) medication, or 
failure to engage a health care professional (HCP).9 Address-
ing this condition early can have significant clinical benefit, 
substantially improving the patient’s quality of life while 
reducing the incidence and/or severity of comorbid disorders, 
including asthma, rhinosinusitis, otitis media, Eustachian 
tube dysfunction, and sleep apnea.3,10,11 Appropriate treat-
ment can help contain costs by reducing absenteeism and 
presenteeism, decreasing complications of AR, and avoiding 
costly adverse effects of OTC medications.3,12,13
The Allergic Rhinitis and its Impact on Asthma (ARIA) 
guidelines propose an evidence-based stepwise approach 
to AR management based on the severity and duration of 
symptoms.3,10 Management strategies include minimizing 
allergen exposure, pharmacotherapy, and immunotherapy. 
ARIA guidelines recommend that pharmacological treat-
ment should consider disease severity and duration; patient’s 
preference; as well as the efficacy, availability, and costs 
of medications.3,10 Intranasal corticosteroids (INCSs) are 
recommended as first-line therapy for moderate to severe 
and/or persistent AR (as well as NAR), and are considered 
the most effective monotherapy for AR in both adults and 
children. They are effective in improving all symptoms of 
AR, including ocular symptoms,14 and are more effective 
than oral antihistamines (OAHs) in relieving nasal conges-
tion.15,16 Second-generation OAHs are considered first-line 
therapy for mild intermittent AR, as they require once daily 
dosing and have a faster onset of action and fewer adverse 
effects than first-generation OAHs. According to ARIA, 
there is insufficient evidence to recommend the combined 
use of OAHs and INCSs, with most of the published studies 
showing no benefits gained by adding other AR treatments 
to INCS therapy.3,17,18
In Australia, data on the nature of prescription and OTC 
medication use for rhinitis, the extent of multiple-therapy use, 
and the costs associated with medication use in the real-life 
management of rhinitis are scarce. In 2010, the majority of 
OAH products available in Australia (125 out of 147) had 
OTC status, making 9 out of 10 OAH products obtainable 
for single therapy or multiple-therapy use without consulting 
a pharmacist or medical practitioner.8 Multiple therapies are 
frequently co-prescribed for rhinitis, despite the lack of clini-
cal evidence to support this practice, and can ultimately affect 
treatment costs to the patient.7,19–21 Owing to the current high 
availability of OTC rhinitis therapies, prior reports based on 
prescription data may underestimate multiple-therapy use.
This study was developed in order to provide more data 
on the burden of rhinitis in Australia as there is a relative pau-
city of research regarding medication expenditure associated 
with multiple-therapy use for rhinitis. Moreover, assessing 
medication expenditure may provide evidence for interven-
tion in terms of both prescription policies and pharmacist 
counseling in OTC medications. The study aimed to describe 
1) the nature and extent of multiple-therapy use for rhinitis in 
Australia using data on therapies purchased with prescription 
or OTC and 2) additional costs incurred by multiple-therapy 
use compared with recommended INCS therapy alone.
Methods
This was a cross-sectional observational study of a historical 
cohort conducted with data from a database collected during 
2013 and 2014. The study was registered with the European 
Network of Centers for Pharmacoepidemiology and Phar-
macovigilance (registration number ENCEPP/SDPP/8507), 
and approved by the Anonymised Data Ethics Protocols 
and Transparency (ADEPT) committee (approval reference 
number ADEPT0215).
Data source
NostraData (https://www.nostradata.com.au/Public/Home/
About) provided a demographically representative dataset 
of anonymous pharmacy transaction data that links doctor 
prescriptions and OTC information. In 2013, there were 5,240 
pharmacies in Australia, with the three eastern seaboard states 
(Queensland, New South Wales and Victoria) accounting for 
77% of the total number.22 The NostraData dataset included 
data from 909 randomly selected pharmacies throughout 
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Australia and provided sufficient geographic coverage of 
the territory and the population, as shown in Table 1. Data 
within this dataset describe the details of valid transactions 
completed at the pharmacy, including name(s) of product(s) 
purchased, prescription or OTC status, postcode of purchase, 
and price paid. As the dataset does not contain patient demo-
graphic information or longitudinal data, it is not possible 
to track individual patient purchases at different NostraData 
pharmacies or on different occasions.
From the pharmacy claims dataset, we assessed pharmacy 
purchases of at least one prescription or OTC rhinitis treat-
ment (used as a proxy for a diagnosis of rhinitis) with or with-
out additional asthma/chronic obstructive pulmonary disease 
(COPD) therapy (used as a proxy for comorbid respiratory 
disease) during 2013 and 2014. Therapeutic classes of rhinitis 
treatments included OAHs, INCSs, intranasal antihistamine 
and corticosteroid combinations, nonsteroidal nasal sprays 
(NSNSs), leukotriene receptor antagonists (LTRAs), eye 
drops (EDs) for allergic conjunctivitis, oral corticosteroids, 
and injectable corticosteroids. A list of drugs included in 
each therapeutic class and the most representative in terms 
of prescription and OTC purchases is presented in Table 2. 
As LTRAs are likely to be purchased for asthma treatment 
rather than rhinitis, and given that individual patients could 
not be tracked in this dataset, LTRAs were included as rhinitis 
therapy only for pharmacy transactions without additional 
asthma/COPD treatment. Similarly, oral and injectable cor-
ticosteroids were included as rhinitis therapy only if they 
were purchased without additional asthma/COPD treatment. 
Therapeutic classes of asthma/COPD treatments included 
short-acting β
2
 agonists, inhaled corticosteroids, long-
acting β
2
 agonists, inhaled corticosteroids and long-acting 
β
2
 agonists combination therapy, short-acting muscarinic 
antagonists, long-acting muscarinic antagonists, cromones, 
and theophyllins.
Study outcomes
Medication-related outcomes for the period 2013 and 2014 
included the following:
1. Count of therapies (ie, number of rhinitis therapies of 
distinct drug class purchased in the same transaction)
2. Drug class of rhinitis therapy purchased as single therapy 
in the transaction
3. Drug class of rhinitis therapy frequently purchased with 
INCSs in the same transaction
4. Proportion of different “classes of therapies” frequently 
purchased OTC with INCSs in the same transaction
5. Treatment cost of single therapy versus multiple therapy 
(ie, average price paid for single versus multiple-therapy 
purchases)
6. Treatment cost of different “classes of therapies” fre-
quently purchased OTC with INCSs (ie, average price 
paid for single- versus dual-therapy purchases)
Data analysis
Data were analyzed using MySQL and Microsoft Excel 
2011 software (Microsoft Corporation, Redmond, WA, 
USA). Descriptive statistics were used to summarize the 
sample characteristics of pharmacy transactions in Australia. 
Pharmacy purchases during the study period were analyzed 
together and reported as average numbers and percentages 
per calendar year. Count of therapies are presented as single, 
multiple, and total number of therapies, and reported as 
absolute numbers and percentages. Combinations of differ-
ent classes of therapies are reported as absolute numbers and 
percentages. The cost of rhinitis therapy is calculated as the 
average price paid by patients in Australian dollars.
Results
Pharmacy transaction data from 909 pharmacies in 2013 
and 2014 were assessed. Sample characteristics of pharmacy 
transactions in different geographic regions over 24 months 
are shown in Table 1. Of the 8,334,472 pharmacy transactions 
assessed, 4,247,193 (51%) included rhinitis therapy. Of the 
4,247,193 pharmacy rhinitis therapy transactions, 4,074,496 
(96%) were without additional asthma/COPD therapy and 
172,697 (4%) were with asthma/COPD therapy.
Table 1 Sample characteristics of pharmacy transactions in 
different geographic regions of Australia over 24 months
State/Territory Pharmacies,  
n
All 
transactions,  
na
All transactions 
including 
rhinitis therapy, 
na
ACT 30 379,839 215,527
NSW 235 2,405,577 1,243,143
NT 3 43,472 21,328
QLD 210 1,738,886 870,898
SA 40 382,983 184,013
TAS 25 168,083 74,339
VIC 203 1,895,063 907,978
WA 119 1,320,569 729,967
Total 909 8,334,472 4,247,193
Notes: aIndividual patients cannot be tracked in this dataset. The data shown are the 
number of pharmacy transactions.
Abbreviations: ACT, Australian Capital Territory; NSW, New South Wales; NT, 
Northern Territory; QLD, Queensland; SA, South Australia; TAS, Tasmania; VIC, 
Victoria; WA, Western Australia.
 
Jo
ur
na
l o
f A
st
hm
a 
an
d 
Al
le
rg
y 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
9.
13
3.
14
8.
27
 o
n 
12
-M
ay
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Journal of Asthma and Allergy 2017:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
156
Smith et al
Count of rhinitis therapy drug classes in 
the same transaction
Of the 4,247,193 pharmacy transactions that included rhinitis 
therapy, 4,074,987 (96.0%) were transactions that included 
a single drug class, and 172,206 (4%) were transactions 
that included multiple drug classes in the same transaction 
from pharmacies across all geographic regions of Australia 
(Table 3).
Classes of rhinitis therapy as single 
therapy in the transaction
Of the 4,074,987 pharmacy transactions that included a single 
drug class in the transaction from pharmacies across all geo-
graphic regions of Australia, 2,955,369 (73%) were OTC and 
prescription purchases of OAHs, and 600,173 (15%) were 
OTC and prescription purchases of INCSs (Table 4).
Classes of rhinitis therapy frequently 
purchased with INCS in the same 
transaction
Of the 172,206 transactions that included multiple drug 
classes in the same transaction from pharmacies across all 
Table 2 List of drugs included in each therapeutic class
Oral antihistamine (OAH) Intranasal  
corticosteroid (INCS)
Nonsteroidal nasal 
spray (NSNS)
Eye drop (ED) 
for allergic 
conjunctivitis
Leukotriene 
receptor  
antagonist  
(LTRA)
Intranasal 
combination 
antihistamine/
corticosteroid
Acrivastine Beclomethasone 
dipropionate 
Azelastine  
hydrochloride
Nedocromil Montelukast Azelestine/fluticasone 
propionate
Alimemazine tartrate Betamethasone  
sodium phosphate
Ipratropium bromide Lodoximide Zafirlukast 
Cetirizine Budesonide Oxymetazoline 
hydrochloride
Olopatadine 
Chlorphenamine Flunisolide Chromolyn Sodium  
Cromoglycate 
Cyproheptadine hydrochloride Flucticasone propionate Antimuscarinic 
Desloratadine Fluticasone furoate Ephedrine  
hydrochloride
 
Diphenhydramine Mometasone furoate Xylometazoline 
hydrochloride
Doxylaminea Triamcinolone acetonide Sodium  
Cromoglycate 
Fexofenadine Oxymetazoline 
hydrochloride
 
Hydroxyzine hydrochloride Levocabastinea
Ketotifen Tramazolinea
Levocetrizine 
Loratadine 
Mizolastine 
Pheniraminea
Promethazine hydrochloride
Notes: aOver-the-counter only.
Abbreviations: ED, eye drop; INCS, intranasal corticosteroid; LTRA, leukotriene receptor antagonist; NSNS, nonsteroidal nasal spray; OAH, oral antihistamine.
Table 3 Count of rhinitis therapy drug classes in the same 
transaction from pharmacies across all geographic regions of 
Australia (N=4,247,193)
Number of drug classes in the same 
transaction
Pharmacy transactions 
na (%)
1 4,074,987 (96)
2 167,993 (3.9)
3 4,150 (0.1)
≥4 63 (<0.001)
Notes: aIndividual patients cannot be tracked in this dataset. The data shown are 
the number of pharmacy transactions.
Table 4 Classes of rhinitis therapy as single therapy in the 
transaction from pharmacies across all geographic regions of 
Australia (N=4,074,987)
Class of rhinitis therapy purchaseda  
as single therapy
Pharmacy transactions 
n (%)
Oral antihistamine (OAH) 2,955,369 (73)
Intranasal corticosteroid (INCS) 600,173 (15)
Nonsteroidal nasal spray (NSNS) 428,583 (10)
Leukotriene receptor antagonist 60,312 (1)
Eye drop (ED) for allergic conjunctivitis 29,054 (0.7)
Intranasal combination therapy of 
antihistamine and corticosteroid
1,496 (0.03)
Notes: aOver-the-counter and prescription.
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geographic regions of Australia, 68,840 (40%) were joint 
purchases of OTC and prescription INCS and OAH (Table 5). 
The remaining 89,763 (52%) transactions included purchases 
of other drug class combinations in the same transaction.
Proportion of OTC “classes of therapy” 
frequently purchased with INCS in the 
same transaction
Of the 72,592 OAHs, 9,769 NSNSs, and 3,673 EDs that 
were purchased OTC with multiple drug classes in the same 
transaction from pharmacies across all geographic regions 
of Australia, 68,237 (94%) OAHs, 9,476 (97%) NSNSs 
and 3,269 (89%) EDs for allergic conjunctivitis were joint 
purchases with INCS (Figure 1). Purchases included OTC 
add-on therapy to INCS, and numbers may therefore differ 
from Table 3, which included OTC and prescription add-on 
therapy to INCS.
Treatment costs
The average cost to patients for purchases of multiple thera-
pies was AU$40 compared to AU$19 for purchases of single 
therapy (Figure 2). The average cost of different “classes of 
therapies” frequently purchased OTC with INCS therapy is 
shown in Figure 3. The average (mean) price paid by patients 
for OTC OAH with INCS therapy was AU$45 compared to 
AU$31 for INCS monotherapy.
Discussion
This study provides a unique insight into the nature and 
extent of multiple-therapy use for rhinitis by patients in 
Australia during a calendar year, and the additional costs 
incurred by multiple-therapy use. It provides data on how 
rhinitis therapy is purchased, the prescribing practices of 
general practitioners (GPs), and self-medication behavior of 
patients in a real-world setting. Our findings revealed that the 
majority of rhinitis therapy transactions were single-therapy 
purchases without additional asthma/COPD therapy. Of 
the single therapies purchased, 73% were OAHs, and only 
15% were guideline-recommended INCS therapy. Dual-
therapy purchases of INCSs and OAHs accounted for 40% 
Table 5 Classes of rhinitis therapy frequently purchased with 
intranasal corticosteroid in transactions that included multiple 
drug classes in the same transaction from pharmacies across all 
geographic regions of Australia (N=172,206)
Class of rhinitis therapy purchaseda  
with INCS
Pharmacy transactions
n (%)
Oral antihistamine 68,840 (40)
Nonsteroidal nasal spray 9,731 (6)
Eye drop for allergic conjunctivitis 3,872 (2)
Notes: aOver-the-counter and prescription.
Abbreviation: INCS, intranasal corticosteroid.
Figure 1 Proportion of OTC oral antihistamine (N=72,952), nonsteroidal nasal 
spray (N=9,769), and eye drop (N=3,673) frequently purchased with intranasal 
corticosteroid in the same transaction from pharmacies across all geographic 
regions of Australia.
Abbreviations: OTC, over-the-counter; INCS, intranasal corticosteroid; OAH, 
oral antihistamine; NSNS, nonsteroidal nasal spray; ED, eye drop.
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Figure 2 Average cost (AUD) of single versus multiple rhinitis therapies.
Abbreviation: AUD, Australian dollars.
50
45
40
35
30
Av
er
ag
e 
co
st
 (A
U
D
)
25
20
15
10
19
40
Single therapy Multiple therapies
5
0
Figure 3 Average cost (AUD) of intranasal corticosteroid purchases with OTC: 
oral antihistamine (N=68,840); nonsteroidal nasal spray (N=9,731); eye drop for 
allergic conjunctivitis (N=3,872) versus intranasal corticosteroid monotherapy 
(N=600,173).
Abbreviations: AUD, Australian dollars; OTC, over-the-counter; INCS, intranasal 
corticosteroid; OAH, oral antihistamine; NSNS, nonsteroidal nasal spray; ED, eye 
drop.
50
45
INCS + OAH INCS + NSNS INCS + ED INCS alone
39 37
31
45
40
35
30
25
Av
er
ag
e 
co
st
 (A
U
D
)
20
15
10
5
0
 
Jo
ur
na
l o
f A
st
hm
a 
an
d 
Al
le
rg
y 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
9.
13
3.
14
8.
27
 o
n 
12
-M
ay
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Journal of Asthma and Allergy 2017:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
158
Smith et al
of multiple-therapy purchases, despite the lack of evidence 
supporting this treatment combination. Patients frequently 
purchased OTC OAHs, NSNSs, and EDs for allergic con-
junctivitis alongside INCSs, resulting in higher financial 
costs (up to AU$21 per treatment episode) compared to 
INCS monotherapy, and potentially a greater overall cost 
burden due to the increased risk of costly adverse effects of 
inappropriate and injudicious medication use.
This is the first large-scale cross-sectional observational 
study assessing the nature and extent of multiple-therapy 
purchases for rhinitis from community pharmacies across 
Australia using prescription and OTC information. Research 
in this area has focused primarily on examining wholesaler 
supplies of rhinitis therapy to pharmacies,8 investigating 
demographics and medication use, and evaluating clinical and 
humanistic outcomes of individuals suffering with rhinitis 
symptoms who visit the pharmacy, using self-report ques-
tionnaire-based surveys without validation of the accuracy 
of the recording of treatments.20,21,23,24 Therefore, exploring 
the nature and extent of multiple-therapy use for rhinitis and 
associated costs incurred by patients, using valid prescription 
and OTC information, was considered important, given the 
increasing size of the OTC medicine market, the number of 
people with rhinitis who choose to self-medicate, the quality 
use of medicines in achieving optimal patient outcomes, and 
the paucity of data about the nature of prescription and OTC 
rhinitis therapy purchases from pharmacies in the Australian 
primary care setting.
The study revealed that the majority of rhinitis therapy 
purchases were single-therapy purchases, of which 73% were 
OAHs and 15% were INCSs. Our results are consistent with 
those from a 2001 longitudinal community pharmacy-based 
study in the United Kingdom (UK), which found that of the 
patient-reported treatments obtained for AR symptoms, over 
70% were OAHs, and 14% were INCSs.20 The AR in Australia 
Report also found that almost three times as many OAHs as 
INCSs were supplied to pharmacies in 2010, and while 125 
out of 147 OAHs had OTC status, only five out of 12 INCS 
products had OTC status, which could explain why people 
prefer purchasing OAHs as they are more readily available.8 
Many people who initially present during the pollen season 
can still have symptoms six months later, suggesting that 
much AR that appears initially to be intermittent is in fact 
persistent in nature.20 Further, while the prevalence of mild 
and moderate to severe AR in Australia has yet to be deter-
mined, a community pharmacy-based survey conducted in 
Belgium found that 95% of survey participants had moderate 
to severe rhinitis.21 Although INCSs are regarded as the gold 
standard for treatment of moderate to severe and/or persistent 
AR by ARIA guidelines,3,10 and first-line treatment of NAR,11 
a minority of individuals in our study purchased this class 
of medication. Underuse of INCSs has also been reported in 
the Asia-Pacific region, with 20% of Australians reporting 
a dislike for nasal sprays as the major reason for not using 
INCSs.25 Only 50% of Australians reported being very satis-
fied with their INCS treatment, and 50% reported they had 
discontinued their INCS treatment. Major reasons cited for 
INCS discontinuation were lack of perceived effectiveness, 
diminution of effect with chronic use, and side effects such as 
retrograde drainage into the esophagus.25 As poor intranasal 
technique and nonadherence to regular continuous therapy 
are factors contributing to uncontrolled symptoms of rhini-
tis, appropriate tools and strategies will be needed to help 
overcome barriers and facilitate the quality use of medicines, 
as well as training and support for pharmacists involved in 
future delivery of pharmacy-based rhinitis care.
An interesting finding in our study was that a majority of 
rhinitis therapy transactions were without additional asthma/
COPD therapy. A possible explanation for this finding could 
be that a proportion of transactions without asthma/COPD 
therapy were by patients with undiagnosed respiratory condi-
tions such as asthma and sinusitis, which are often associated 
with some types of rhinitis.3,10,11 In Australia, at least 30% of 
patients with known AR also have asthma, and up to 80% of 
people with asthma have coexisting AR.26 Both AR and NAR 
are risk factors for the development of asthma,27 and AR has 
been shown to be associated with worse asthma control in 
children and adults.28,29 Given that the upper and lower airway 
is regarded as “a united airway”,30 ARIA recommends that 
in patients with persistent AR, health care providers should 
screen for asthma, and in those with asthma, they should 
screen for rhinitis.3,10 Other possible explanations for this 
finding were that a proportion of transactions without asthma/
COPD therapy were destined to individuals with chronic 
respiratory conditions or that most people with rhinitis and 
coexisting chronic respiratory disease may not manage their 
symptoms with pharmacotherapy but rather immunotherapy.
In this study, the most common multiple-therapy purchase 
was a combination of INCS and OAH, despite the lack of 
evidence supporting this treatment combination.3,10 This 
dual-therapy regimen has been observed in a large-scale 
retrospective study,31 which found that dual INCS and OAH 
therapy was common at the end of the UK pollen season 
(March–August), as initial OAHs or INCS monotherapy 
received at the start of the season proved to be insufficient in 
controlling symptoms for many AR patients. The study also 
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found that monotherapy with INCS at the start of the season 
failed to control symptoms in about 25% of AR patients, a 
high proportion given their superiority of effect according to 
the guidelines.3,10,11,32 Factors that could contribute to failure 
of INCS monotherapy in controlling symptoms include 
mixed rhinitis,1,33 comorbidities,3,11 poor inhaler technique,32 
polysensitization,34 nonadherence to long-term therapy, and 
severe chronic upper airways disease.35 For many AR patients, 
INCS monotherapy does not provide the expected level of 
relief,25,36 highlighting the need for pragmatic strategies to 
help improve long-term adherence, optimize intranasal device 
technique, as well as more effective AR treatment options.
Our study also found that patients frequently purchased 
OTC OAHs, NSNSs, and EDs alongside INCSs, resulting in 
higher financial costs (up to AU$21 per treatment episode) 
for patients. AR is often regarded as a background noise, a 
nuisance, and a trivial disease, as it is not life threatening. 
For those reasons, AR is frequently self-managed by patients 
with OTC treatments from community pharmacies, and the 
pharmacist, therefore represents the first point of contact for 
advice on appropriate medication.19,37–39 Over 60% of rhinitis 
patients are known to self-medicate, often with inappropri-
ate medication, leading to poorly controlled symptoms and 
suboptimal management.20,21 Multiple-therapy use is common 
among AR patients who often self-medicate with OTC treat-
ments without seeking pharmacist advice.19–21 There appears 
to be a failure on the part of health care providers to translate 
the evidence that INCSs are the most effective monotherapy 
for moderate to severe and/or persistent rhinitis in both adults 
and children into clinical practice. INCSs are more effec-
tive than other therapies in improving all symptoms of AR, 
and quality of life, and are more cost-effective than other 
AR therapies. The study results highlight the need for HCP 
engagement, especially at the pharmacy level, which will be 
extremely important if we wish to ensure that the purchase of 
rhinitis treatment is appropriate and that their use is optimal. 
This is the only way to ensure that patients continue to use 
guideline-recommended medications appropriately.
Strengths and limitations of this study
This large dataset included pharmacy transaction data from 
909 Australian community pharmacies and information on 
4,247,193 rhinitis treatments for “real-life” patients with 
or without additional respiratory disease in 2013 and 2014. 
Data related to rhinitis therapy underwent rigorous quality 
assurance procedures prior to statistical analyses. As the 
dataset used prescription and OTC information, rather than 
patient-reported outcomes, it provided a unique insight into 
prescribing and self-medication behavior, and the significant 
burden posed on community pharmacy to address the needs 
of people with rhinitis symptoms. The sample of pharmacy 
transactions involving OAHs and INCSs treatments is rep-
resentative of the Australian population as a whole based on 
the latest published data of pharmaceutical wholesale supply 
of OAHs and INCSs to community pharmacies.8 Finally, 
another strength of the study is its observational nature, which 
allowed a “snapshot” of the current state of rhinitis treatment 
purchases via prescription and OTC supply in Australia. This 
approach provides insight into prescriber behavior and patient 
purchasing behavior that would have been difficult to obtain 
through other approaches, such as online surveys, which can 
misrepresent patient and prescriber behavior.
The limitations of the study were associated with the 
cross-sectional design, lack of patient demographic data, 
and lack of longitudinal data, which may have resulted in an 
underestimation of multiple-therapy rates, as patients may 
not have purchased all their rhinitis therapies in the same 
transaction. In a longitudinal study of AR patients recruited 
through community pharmacies in the UK, 16% of patients 
purchased additional treatments from the pharmacy 5 days 
after their original purchase, and 16% and 18% purchased 
additional treatments after 4 and 8 weeks, respectively.20 
Additionally, we used prescription and OTC purchases of 
rhinitis therapy as a proxy for a rhinitis diagnosis and asthma/
COPD therapy as a proxy for a diagnosis of asthma or COPD. 
There is, however, a possibility that treatments classified as 
rhinitis therapy could have been purchased OTC or by pre-
scription for another indication such as eczema and allergic 
conjunctivitis, although a UK study has shown that >60% of 
patients prescribed OAH had a diagnosis of rhinitis.40 Further, 
in this study it was not possible to check whether therapies 
purchased together in the dataset were all destined to the 
same patient, nor was it possible to document purchases or 
rhinitis therapy from pharmacies outside NostraData cover-
age. Another limitation was that we were unable to determine 
the cost burden associated with inappropriate use of medi-
cations, this being a major issue identified in this research. 
That is, although we were able to determine the unit costs of 
purchases, this does not mean that there was no additional 
cost burden due to the overall cost burden.
Conclusion
This large-scale retrospective observational study described 
the nature and extent of multiple-therapy use for rhinitis in 
a real-world setting and the additional costs incurred by 
multiple-therapy use compared with recommended INCS 
therapy alone. It highlighted the significant burden posed on 
community pharmacy to address the needs of people with 
 
Jo
ur
na
l o
f A
st
hm
a 
an
d 
Al
le
rg
y 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
9.
13
3.
14
8.
27
 o
n 
12
-M
ay
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Journal of Asthma and Allergy 2017:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
160
Smith et al
rhinitis symptoms, and the failure to translate the evidence 
that INCSs are the most effective monotherapy for moder-
ate to severe and/or persistent rhinitis into clinical practice. 
HCP engagement, especially at the pharmacy level, will be 
extremely important if we wish to ensure that the purchase of 
rhinitis treatment is appropriate and that their use is optimal.
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